Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 6125 | 1462 | 42.9 | 85% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 412 | 16030 | GENE DELIVERY//GENE THERAPY//POLYETHYLENIMINE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | MOL MED GENE THER Y UNIT | Address | 35 | 67% | 2% | 31 |
| 2 | GUTLESS | Author keyword | 21 | 90% | 1% | 9 |
| 3 | HELPER DEPENDENT ADENOVIRUS | Author keyword | 17 | 68% | 1% | 15 |
| 4 | HELPER DEPENDENT | Author keyword | 15 | 77% | 1% | 10 |
| 5 | HELPER DEPENDENT ADENOVIRAL VECTORS | Author keyword | 12 | 75% | 1% | 9 |
| 6 | GUTLESS ADENOVIRUS | Author keyword | 8 | 100% | 0% | 5 |
| 7 | HELPER DEPENDENT ADENOVIRAL VECTOR | Author keyword | 6 | 53% | 1% | 8 |
| 8 | ADENOVIRUS VECTORS | Author keyword | 6 | 26% | 1% | 18 |
| 9 | LIVER DIRECTED GENE THERAPY | Author keyword | 4 | 75% | 0% | 3 |
| 10 | MT STATES MED | Address | 4 | 75% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | RECOMBINANT ADENOVIRUSES | 59 | 28% | 12% | 179 |
| 2 | VIRAL CODING SEQUENCES | 54 | 64% | 4% | 54 |
| 3 | CRE MEDIATED EXCISION | 35 | 64% | 2% | 34 |
| 4 | FULL LENGTH DYSTROPHIN | 32 | 41% | 4% | 60 |
| 5 | TYPE 5 | 29 | 24% | 7% | 109 |
| 6 | VIRAL ANTIGENS | 26 | 30% | 5% | 71 |
| 7 | RECOMBINANT ADENOVIRUS | 25 | 13% | 12% | 173 |
| 8 | MINIDYSTROPHIN GENE | 21 | 42% | 3% | 39 |
| 9 | HEPATOCYTES IN VIVO | 16 | 36% | 3% | 37 |
| 10 | PERSISTENT TRANSGENE EXPRESSION | 15 | 67% | 1% | 14 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Helper-dependent adenoviral vectors for gene therapy | 2005 | 94 | 89 | 85% |
| Helper-dependent adenoviral vectors for liver-directed gene therapy | 2011 | 21 | 81 | 48% |
| Adenovirus vectors for gene delivery | 1999 | 236 | 61 | 57% |
| Challenges in Manufacturing Adenoviral Vectors for Global Vaccine Product Deployment | 2014 | 5 | 34 | 65% |
| Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors | 2008 | 44 | 48 | 54% |
| From the first to the third generation adenoviral vector: What parameters are governing the production yield? | 2009 | 18 | 113 | 81% |
| Production of first generation adenovirus vectors: a review | 2000 | 83 | 64 | 77% |
| Advances in helper-dependent adenoviral vector research | 2008 | 27 | 145 | 66% |
| Molecular basis of the inflammatory response to adenovirus vectors | 2003 | 257 | 48 | 35% |
| New insights into stability of recombinant adenovirus vector genomes in mammalian cells | 2012 | 10 | 90 | 41% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MOL MED GENE THER Y UNIT | 35 | 67% | 2.1% | 31 |
| 2 | MT STATES MED | 4 | 75% | 0.2% | 3 |
| 3 | BOARD GOVERNORS GENE THER EUT | 3 | 57% | 0.3% | 4 |
| 4 | MOL CELLULAR ENGN | 2 | 11% | 1.2% | 18 |
| 5 | LIBIN GENE THER Y UNIT | 2 | 50% | 0.2% | 3 |
| 6 | MED MOL MED PHARMACOL | 2 | 36% | 0.3% | 4 |
| 7 | BIOCHEM LA PLATA | 1 | 50% | 0.1% | 2 |
| 8 | MEDGENE THER EUT | 1 | 100% | 0.1% | 2 |
| 9 | RHONE POULENC GENCELL | 1 | 50% | 0.1% | 2 |
| 10 | ANIM BIOTECHNOL GENE THER Y CBATEG | 1 | 23% | 0.3% | 5 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000277965 | COXSACKIE ADENOVIRUS RECEPTOR//GENE TRANSFER REGULAT//COXSACKIE AND ADENOVIRUS RECEPTOR |
| 2 | 0.0000244113 | GENE MED GRP//GENEMED GRP//EXPT TREATMENT CYST FIBROSIS |
| 3 | 0.0000162107 | W ROXBURY VA HOSP//HERPES SIMPLEX VIRUS VECTOR//HELPER VIRUS FREE PACKAGING |
| 4 | 0.0000125941 | HEMAGGLUTINATING VIRUS OF JAPAN//GAX//HVJ LIPOSOME |
| 5 | 0.0000117809 | HYDRODYNAMICS BASED PROCEDURE//HYDRODYNAMICS BASED TRANSFECTION//HYDRODYNAMIC DELIVERY |
| 6 | 0.0000116974 | CYTOSINE DEAMINASE//SUICIDE GENE THERAPY//HERPES SIMPLEX VIRUS THYMIDINE KINASE |
| 7 | 0.0000115626 | INSULIN GENE THERAPY//DIABETES GENE THERAPY//ENDOCRINOL METAB SECT 111 |
| 8 | 0.0000096775 | SKIN GENE THERAPY//HUMAN CLOTTING FACTOR IX//CLOTTING FACTOR IX |
| 9 | 0.0000096616 | BIOL MOL ELADIO VINUELA//PHAGE PHI 29//LINEAR DNA REPLICATION |
| 10 | 0.0000091602 | ADENO ASSOCIATED VIRUS//AAV//POWELL GENE THER Y |